放射性皮肤炎市场－全球产业规模、份额、趋势、机会及预测（依产品、通路、地区及竞争格局划分，2021-2031年）

全球放射性皮肤炎治疗市场预计将从 2025 年的 4.8718 亿美元成长到 2031 年的 5.8648 亿美元，复合年增长率为 3.14%。

该市场由一系列专业产品组成，包括口服药物、亲水性敷料和外用製剂，旨在预防和控制癌症患者放射引起的皮肤反应。主要成长要素包括全球需要放射治疗的癌症患者人数不断增加，以及临床上对实证支持治疗以提高患者生活品质的日益关注。根据美国癌症协会 (ACS) 的报告，预计到 2025 年，美国将新增 2,041,910 例癌症病例，这将显着增加易受辐射中毒影响的患者数量。

然而，市场扩张面临许多障碍，包括先进创伤护理製剂的高昂成本，以及新兴国家缺乏预防性皮肤治疗的标准化报销政策。这些经济障碍限制了患者获得优质治疗方案的机会，并阻碍了注重成本的医疗保健系统采用高效产品。

市场驱动因素

全球癌症发生率的不断上升是全球放射性皮肤炎市场的主要驱动因素。恶性肿瘤发生率的上升直接导致接受放射治疗的患者人数增加。随着癌症诊断数量的激增，用于应对常见副作用（例如放射引起的皮肤反应）的支持性护理也必须相应增加，从而扩大了需要预防性和治疗性皮肤病护理的患者群体。根据世界卫生组织（WHO）国际癌症研究机构（IARC）于2024年2月发布的题为《全球癌症负担日益加重》的新闻稿，预计到2050年，新增癌症病例将超过3500万例，比2022年估计的2000万例增长77%。

同时，市场正透过策略联盟和产品系列扩张进行转型，主要企业积极拓展其先进创伤护理产品线，以治疗复杂的皮肤损伤。製造商正加大对高效配方和亲水性敷料的投资，推动专业护肤领域收入的显着成长。这一成长动能在近期发布的财务报告中可见一斑，例如康维特集团（ConvaTec Group）在2024年3月发布的报告显示，其先进创伤护理部门在2023年实现了9.5%的有机收入增长，主要得益于抗菌药物和生物製药的推动。同样，科乐普公司（Coloplast A/S）在2024年11月宣布，其先进创伤护理业务在2023/24财年实现了10%的内部成长，印证了全球对先进组织修復解决方案的强劲需求。

市场挑战

全球放射性皮肤炎治疗市场面临许多成长障碍，主要原因是先进创伤护理製剂高成本且健保报销政策不一致。虽然特製亲水性敷料和外用药物在控制放射性皮肤反应方面疗效显着，但其高昂的价格对注重成本的医疗机构而言构成了一道难以逾越的门槛。在许多地区，预防性皮肤治疗不在强制性医疗保险的覆盖范围内，迫使患者自费或导致医疗机构不愿储备此类产品。这种经济上的阻碍限制了患者获得最佳治疗的机会，并迫使医疗机构转向价格更低的非专利药，从而导致放射性皮肤炎专用产品的商业性分销减少。

肿瘤科诊疗机构面临的这种经济负担直接限制了高利润辅助治疗方案的采用。由于外部经济压力导致临床预算收紧，非核心辅助产品的采购往往会减少。根据美国放射肿瘤学会2024年的数据，过去十年中，联邦医疗保险（Medicare）对放射治疗服务的累积报销额下降超过20%，给治疗中心带来了巨大的财务压力。这种严峻的报销环境迫使诊所尽可能降低营运成本，这直接抑制了高价值放射性皮肤炎治疗产品的市场渗透，并阻碍了製造商的收入成长。

市场趋势

全球放射性皮肤炎治疗市场正日益青睐光生物调节疗法（PBMT）来控制症状。传统的局部治疗正逐渐被基于光的组织再生技术所取代。这一转变源于PBMT能够从细胞层面减轻炎症，从而在放射性皮肤毒性发展为开放性伤口之前，限制其严重程度。临床验证证实PBMT在维持高剂量放射治疗期间皮肤完整性的有效性，加速了其应用。一项题为「光生物调节疗法对癌症患者急性放射性皮肤炎的影响」的研究于2024年10月发表在《放射治疗与肿瘤学》杂誌上，该研究发现，PBMT显着降低了严重皮肤反应的负担，与标准对照组相比，2级和3级皮肤炎的风险降低了0.36倍。

同时，成膜凝胶技术，尤其是硅基屏障膜，正迅速普及。这些技术旨在提供比传统水基乳膏更好的预防性保护，形成半封闭、自干的保护层，模拟角质层。这可以防止经表皮水分流失，且避免了厚重药膏引起的浸渍风险。这项创新技术能够在不干扰放射治疗的情况下提供持续的皮肤保护，因此在肿瘤中心得到了更广泛的应用。根据发表于2024年9月《癌症支持治疗》杂誌上题为「StrataXRT用于预防乳癌急性放射性皮肤炎」的论文，使用这些先进的屏障凝胶显着减少了放射治疗期间的湿性脱屑，仅有23.3%的患者出现这种情况。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球放射性皮肤炎市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（外用药物（皮质类固醇、亲水性乳膏、抗生素等）、口服药物、敷料（水凝胶及亲水胶体敷料、无线屏障膜、蜂蜜浸渍纱布、硅涂层敷料等））
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美放射性皮肤炎市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲放射性皮肤炎市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区放射性皮肤炎市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲放射性皮肤炎市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲放射性皮肤炎市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球放射性皮肤炎市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• 3M Company
• Bausch Health Companies Inc.
• Bayer AG
• BMG PHARMA SpA
• Charles River Laboratories International Inc.
• ConvaTec Group plc
• Helsinn Healthcare SA
• ICON plc
• Integra LifeSciences
• Molnlycke Health Care AB
• Stratpharma AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Radiodermatitis Market is projected to expand from USD 487.18 Million in 2025 to USD 586.48 Million by 2031, reflecting a compound annual growth rate of 3.14%. This market consists of a specialized portfolio of oral pharmaceuticals, hydrophilic dressings, and topical agents aimed at preventing or managing radiation-induced skin reactions in oncology patients. The primary growth drivers include the increasing global prevalence of cancer necessitating radiotherapy and a heightened clinical focus on evidence-based supportive care to enhance patient quality of life. As reported by the American Cancer Society, a total of 2,041,910 new cancer cases are expected in the United States in 2025, which significantly enlarges the patient population susceptible to radiation toxicity.

However, market expansion faces a substantial obstacle in the form of prohibitive costs for advanced wound care formulations and a lack of standardized reimbursement policies for prophylactic dermatological treatments in emerging economies. These financial barriers restrict patient access to premium management solutions and limit the adoption of higher-efficacy products within cost-sensitive healthcare systems.

Market Driver

The rising global incidence of cancer acts as the primary engine driving the Global Radiodermatitis Market, as higher rates of malignancy directly lead to an increased number of patients undergoing radiation therapy. This surge in cancer diagnoses requires a proportional increase in supportive care interventions to handle common side effects like radiation-induced skin reactions, resulting in a growing patient pool that needs prophylactic and therapeutic dermatological management. According to the World Health Organization's International Agency for Research on Cancer (IARC) in their February 2024 press release 'Global cancer burden growing', new cancer cases are predicted to exceed 35 million by 2050, marking a 77% increase from the estimated 20 million cases in 2022.

At the same time, the market is being transformed by strategic collaborations and product portfolio expansions, with key industry players actively diversifying their advanced wound care offerings to treat complex skin injuries. Manufacturers are investing heavily in high-efficacy formulations and hydrophilic dressings, which is driving significant revenue growth in the specialized skincare sector. This momentum is highlighted in recent financial reports; for instance, Convatec Group Plc reported in March 2024 that its Advanced Wound Care category achieved 9.5% organic revenue growth in 2023, fueled by antimicrobials and biologics. Similarly, Coloplast A/S announced in November 2024 that its Advanced Wound Care business saw 10% organic growth for the 2023/24 year, underscoring the strong global demand for advanced tissue repair solutions.

Market Challenge

The Global Radiodermatitis Market encounters a significant barrier to growth due to the high costs of advanced wound care formulations and the lack of consistent reimbursement policies. Although specialized hydrophilic dressings and topical agents provide superior efficacy in managing radiation-induced skin reactions, their premium pricing creates a steep entry barrier for cost-sensitive healthcare systems. In many regions, prophylactic dermatological treatments are not covered by essential insurance, forcing patients to pay out-of-pocket or causing clinics to avoid stocking these items. This economic friction limits patient access to optimal care and compels providers to rely on cheaper, generic alternatives, thereby reducing the commercial volume of specialized radiodermatitis products.

This financial strain on oncology practices directly restricts the adoption of high-margin supportive care solutions. As clinical budgets tighten due to external economic pressures, the purchase of non-core ancillary products is often curtailed. Data from the American Society for Radiation Oncology in 2024 indicates that cumulative Medicare reimbursement reductions for radiation therapy services have exceeded 20% over the last decade, placing immense fiscal pressure on treatment centers. This difficult reimbursement environment forces clinics to minimize operational spending, which directly hampers the market penetration of premium radiodermatitis treatments and stalls revenue growth for manufacturers.

Market Trends

The Global Radiodermatitis Market is increasingly adopting Photobiomodulation Therapy (PBMT) for symptom management, moving from solely topical interventions to light-based tissue regeneration methods. This shift is driven by the therapy's ability to reduce inflammation at the cellular level, thereby lessening the severity of radiation-induced skin toxicity before it progresses to open wounds. Adoption is accelerating as clinical bodies confirm its efficacy in preserving skin integrity during high-dose radiation schedules. A study published in Radiotherapy and Oncology in October 2024, titled 'Effects of photobiomodulation therapy for acute radiation dermatitis in patients with cancer', found that this therapy significantly reduced the burden of severe skin reactions, showing a risk difference of -0.36 for grade 2 and 3 dermatitis compared to standard control groups.

Concurrently, there is a rapid expansion of film-forming gel technologies, particularly silicone-based barrier films, which are designed to offer better prophylactic protection than traditional aqueous creams. These formulations create a semi-occlusive, self-drying shield that mimics the stratum corneum, preventing transepidermal water loss without the risk of maceration associated with heavy ointments. This innovation allows for continuous skin protection that does not interfere with radiation delivery, leading to higher utilization rates in oncology centers. According to an article in Supportive Care in Cancer from September 2024 titled 'StrataXRT for the prevention of acute radiation dermatitis in breast cancer', the use of these advanced barrier gels resulted in substantial preventative efficacy, with only 23.3% of treated patients developing moist desquamation during the radiotherapy course.

Key Market Players

• 3M Company
• Bausch Health Companies Inc.
• Bayer AG
• BMG PHARMA S.p.A.
• Charles River Laboratories International Inc.
• ConvaTec Group plc
• Helsinn Healthcare SA
• ICON plc
• Integra LifeSciences
• Molnlycke Health Care AB
• Stratpharma AG

Report Scope

In this report, the Global Radiodermatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiodermatitis Market, By Product

• Topical(Corticosteroids, Hydrophilic Creams, Antibiotics, Others)
• Oral
• Dressings (Hydrogel and Hydrocolloid Dressings, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressings, Others)

Radiodermatitis Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Radiodermatitis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiodermatitis Market.

Available Customizations:

Global Radiodermatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiodermatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Topical(Corticosteroids, Hydrophilic Creams, Antibiotics, Others), oral, dressings (Hydrogel and Hydrocolloid Dressings, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressings, Others))
  • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Radiodermatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Radiodermatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Radiodermatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Radiodermatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Radiodermatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Radiodermatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Radiodermatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Radiodermatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Radiodermatitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Radiodermatitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Radiodermatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Radiodermatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Radiodermatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Radiodermatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Radiodermatitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Radiodermatitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Radiodermatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Radiodermatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Radiodermatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Radiodermatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. South America Radiodermatitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Radiodermatitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Radiodermatitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Radiodermatitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Radiodermatitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. 3M Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bausch Health Companies Inc.
• 15.3. Bayer AG
• 15.4. BMG PHARMA S.p.A.
• 15.5. Charles River Laboratories International Inc.
• 15.6. ConvaTec Group plc
• 15.7. Helsinn Healthcare SA
• 15.8. ICON plc
• 15.9. Integra LifeSciences
• 15.10. Molnlycke Health Care AB
• 15.11. Stratpharma AG

16. Strategic Recommendations

17. About Us & Disclaimer